Consequently, the rationale for using immunotherapy in BC is compelling, and FDA approvals of all 5 antibodies targeting ICIs such as CTLA-4, PD-L1, and PD-1 further support this approach in BC [19]. This evidence concerns the gene CD274 and breast cancer.